Evaluation of mAb 4D7 IC efficacy in a U266 CDX model implanted in NSG mice. (A) Experimental timeline illustrating U266 tumor implantation (day 0), pNK cell inoculation (day 7), hIL-15 supplementation and 4D7/control treatments from day 9, and tumor volume measurement schedule. (B) Tumor volume measurements of the different treatment groups, including vehicle, hIgG1, and mAb 4D7. (C) Ki67 staining quantification is presented as a boxplot. (D) Representative images of Ki67 staining in tumor sections from each treatment group. ∗∗P < .01; ∗∗∗∗P < .0001 (ANOVA). ns, not significant; pNK, primary NK cells.
Figure 6.

Evaluation of mAb 4D7 IC efficacy in a U266 CDX model implanted in NSG mice. (A) Experimental timeline illustrating U266 tumor implantation (day 0), pNK cell inoculation (day 7), hIL-15 supplementation and 4D7/control treatments from day 9, and tumor volume measurement schedule. (B) Tumor volume measurements of the different treatment groups, including vehicle, hIgG1, and mAb 4D7. (C) Ki67 staining quantification is presented as a boxplot. (D) Representative images of Ki67 staining in tumor sections from each treatment group. ∗∗P < .01; ∗∗∗∗P < .0001 (ANOVA). ns, not significant; pNK, primary NK cells.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal